In Part A of the trial, subjects will be given nine intravenous infusions of either the drug or placebo over a six-month period.

A step-up in protectionist threats between Canada and the US prompted another negative session on Wall Street on Tuesday, ...

The stock's fall snapped a seven-day winning streak.

Sage Therapeutics (NASDAQ:SAGE) stock drops as Bank of America issues an Underperform rating citing an end to Biogen's (BIIB) ...

Ionis Pharmaceuticals IONS announced that the European Commission (“EC”) has approved Wainzua (eplontersen) for treating ...